# A Phase 1 Study of the Safety and Tolerability of ICM20 in Adults

> **NCT05523596** · PHASE1 · COMPLETED · sponsor: **IC-MedTech Corporation** · enrollment: 13 (actual)

## Conditions studied

- Safety Issues

## Interventions

- **DRUG:** ICM20
- **DRUG:** Benznidazole

## Key facts

- **NCT ID:** NCT05523596
- **Lead sponsor:** IC-MedTech Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-08-20
- **Primary completion:** 2025-10-03
- **Final completion:** 2025-10-03
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2026-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05523596

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05523596, "A Phase 1 Study of the Safety and Tolerability of ICM20 in Adults". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05523596. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*